RECRUITING Not applicable ClinicalTrials.gov

Safety and Short-term Outcomes of Modular Robotic System for Siewert II/III Gastroesophageal Junction Cancer

Sponsor: The First Hospital of Jilin University • ClinicalTrials.gov ID: NCT07790809

Registry updated: 2026-09-02

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Siewert type II/III gastroesophageal junction (GEJ) adenocarcinoma is a challenging malignancy located at the anatomical transition between the esophagus and stomach. Due to its complex anatomical location and mixed biological characteristics of esophageal and gastric cancers, the optimal surgical strategy remains controversial. Current surgical approaches vary in terms of operative access, extent of resection, and lymph node dissection. Although minimally invasive laparoscopic and integrated robotic surgery have demonstrated potential advantages in improving perioperative outcomes, limitations remain when managing complex procedures involving both abdominal and mediastinal fields. Split-type robotic surgical systems, characterized by independently movable robotic carts, provide greater flexibility in robotic arm positioning and may overcome some limitations associated with conventional integrated robotic platforms, particularly in extensive multi-quadrant procedures requiring simultaneous abdominal and mediastinal lymph node dissection. However, clinical evidence regarding the safety and effectiveness of split-type robotic surgery for Siewert type II/III GEJ cancer remains limited. This prospective single-arm clinical study aims to evaluate the feasibility, safety, and short-term surgical outcomes of split-type robotic radical surgery for patients with Siewert type II/III GEJ adenocarcinoma. The study will assess perioperative outcomes, including operative characteristics, postoperative complications, lymph node dissection quality, and short-term recovery parameters. The findings of this study are expected to provide preliminary clinical evidence regarding the application of split-type robotic technology in complex GEJ cancer surgery and support future large-scale clinical investigations.

Interventions

Robotic-assisted radical resection for Siewert type II/III gastroesophageal junction cancer (Procedure)
Patients will undergo totally robotic-assisted radical surgery for Siewert type II/III gastroesophageal junction cancer. The surgical procedure includes robotic-assisted tumor resection and lymph node dissection according to standard oncologic principles.

Eligibility criteria

Inclusion Criteria: 1. Age between 18 and 80 years, inclusive, regardless of sex. 2. Histologically and/or cytologically confirmed Siewert type II or type III gastroesophageal junction tumor, with clinical staging according to AJCC 8th edition TNM classification indicating suitability for curative surgical resection. 3. Adequate organ function as assessed by the investigator before surgery. 4. Provision of written informed consent and willingness to participate in the study. 5. Ability and willingness to comply with study procedures and follow-up requirements. 6. ECOG performance status of 0-1. 7. Absence of distant metastasis confirmed by preoperative thoracoabdominal and pelvic CT or PET-CT. Exclusion Criteria: 1. Patients with body mass index (BMI) \<18.5 kg/m² or BMI ≥35 kg/m². 2. Patients with severe cardiac, pulmonary, neurological, hepatic, or renal diseases that may prevent tolerance of surgery or anesthesia. 3. Patients unable to tolerate pneumoperitoneum or considered by the investigator to have extensive intra-abdominal adhesions or other conditions preventing safe establishment of pneumoperitoneum. 4. Patients with severe coagulation disorders that contraindicate minimally invasive surgery. 5. Patients with active pulmonary tuberculosis. 6. Patients with severe uncontrolled diseases, acute infections, severe physical deterioration, massive ascites, active intra-abdominal bleeding, or shock. 7. Patients with metastatic lymph nodes fused together or encasing major blood vessels, making curative resection infeasible. 8. Patients with previous abdominal/pelvic surgery, radiotherapy, or chemotherapy that may affect the feasibility of laparoscopic or robotic surgery. 9. Pregnant or breastfeeding women. 10. Patients currently participating in other clinical trials involving investigational drugs or medical devices. 11. Patients considered unsuitable for this study by the investigator.

Conditions

Siewert Type II/III Gastroesophageal Junction Adenocarcinoma

Locations

First Hospital of Jilin Universiry — Changchun, Jilin, China

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment